RESUMEN
Oils from animal sources have been used for centuries in the management of diseases. This research was conducted to screen the ex vivo and in vivo toxicity of quail egg yolk oil (QEYO) extracts and assess their effects on the management of hypertension in rats. QEYO was extracted using gentle heating (GH) and n-hexane (NHN). The extracts were subjected to toxicity testing using the hen's egg test on chorioallantoic membrane (HET-CAM) and bovine corneal histology test. Acute and sub-chronic toxicity (28 days) were evaluated in rats. Hypertension was induced in rats by administering 80 mg/kg of Nω-L-Arginine Methyl Ester (L-NAME) per day for 28 days. Treatments commenced on the 14th day; Nifedipine at 30 mg/kg and 1 mL of distilled water were administered as positive and negative controls. Blood pressure (BP), lipid profiles, and oxidative stress markers were quantified. No irritation was observed using the HET-CAM test in the egg treated with both extracts. Bovine corneal histology showed no lesions in all treated groups. No signs of toxicity were observed in either acute or sub-chronic toxicity studies. A significant reduction in blood pressure was observed in rats treated with the extracts (p < 0.05). Changes in total cholesterol (TC), triglycerides (TGs), low-density lipoproteins (LDLPs), and high-density lipoproteins (HDLPs) were not significant compared to the control (p > 0.05). Oxidative stress markers (SOD and CAT) increased significantly in the treated groups compared to the control, while the malondialdehyde levels decreased (p < 0.05). QEYO was safe in both ex vivo and in vivo studies and can be said to have the potential to lower blood pressure as well as cardio-protective effects in hypertensive rats. This research provides evidence based on which QEYO could be used safely as an adjuvant therapy in eye drops and cosmetics and can be considered an effective choice for preventing hypertension.
RESUMEN
Quail egg yolk oil (QEYO) has a rich history of medicinal use, showcasing heightened antioxidant and bioactive properties in our prior studies. This positions QEYO as a promising candidate for therapeutic and cosmetic applications. In this investigation, QEYO was extracted using ethanol/chloroform and 2-propanol/hexane solvents. GC-MS and FTIR analyses quantified 14 major bioactive compounds in the ethanol/chloroform fraction and 12 in the 2-propanol/hexane fraction. Toxicity evaluations in fruit flies, spanning acute, sub chronic, and chronic exposures, revealed no adverse effects. Negative geotaxis assays assessed locomotor activity, while biochemical assays using fly hemolymph gauged antioxidant responses. Real-time PCR revealed the relative expression levels of the antioxidant and anti-inflammatory genes. FTIR spectra indicated diverse functional groups, and the GC-MS results associated bioactive compounds with the regulation of the anti-inflammatory genes EIGER and UPD2. While no significant change in SOD activities was noted, male flies treated with specific QEYO doses exhibited increased catalase activity and total antioxidant capacity, coupled with a significant decrease in their malondialdehyde levels. This study offers valuable insights into the bioactive compounds of QEYO and their potential regulatory roles in gene expression.
RESUMEN
The extensive and indiscriminate use of antibiotics is known to contribute to antimicrobial resistance. Unfortunately, there are no public records of antimicrobial use (frequency or dosage) administered to animals in two major CARICOM (Caribbean Community) countries: Trinidad and Tobago, and Jamaica. Surveillance would promote amendments and discussion on a Caribbean antimicrobial-use protocol. In this study, an online survey was conducted using cross-sectional qualitative interviews via email, targeting veterinary clinicians working in clinics and farms in Trinidad and Jamaica, to identify how antimicrobials are used in the two countries. Out of the thirty-two (32) clinicians interviewed in Trinidad, 22 (68.75%) were small animal practitioners, and 10 (45.45%) were mixed practitioners. While in Jamaica, a total of Twenty six (26) clinicians responded, of which 17 of them (65.38%) were small animal practitioners and nine (34.62%) were mixed practitioners. A total of 95.2% of clinics and farms in Jamaica and 87.1% in Trinidad did not use standard antimicrobial protocols, which could be due to the limited availability of resources. The broad-spectrum antibiotic, amoxicillin, and amoxicillin/clavulanic acid were the most commonly used drugs in small animal practices in both countries (71.9% and 53.8% in dogs), (78.1% and 65.9% in cats); amoxicillin is also used frequently in mixed animal practice in Jamaica (44.4% in goats, 33.3% in cattle and 22.2% in sheep and pigs), while procaine penicillin and streptomycin was the most frequently used in mixed practice in Trinidad (60% in cattle and goats, 50% in sheep), which could explain the potentially increased risk of antimicrobial resistance.
RESUMEN
Since the announcement by the World Health Organization (WHO) of an outbreak of a contagious respiratory viral pneumonia in Wuhan, China, in December 2019 (later named as COVID-19), several research works have been carried out to unstitch the therapeutic options and combat the disease using various aproaches and modalities. These works are currently at different clinical trial stages, and their results may be determined by the outcome of the ongoing trial process. There is the need for a collection of information regarding the availlable therapeutic options related to COVID-19. this article therefore reviewed emerging and re-emerging therapeutic compounds/drugs used in COVID-19 management and reports of clinical trials, with the view to summarize and highlight their prospect and possible adverse effects to allow more extensive choice by clinicians, researchers, and policymakers. The approach used involved retrieval of related collections found in selected repositories including, Medline, Scopus, PubMed, and Google scholar. Only experimental or clinical studies were included. Out of the 39 materials retrieved, 26 (66.67%) studies were based on clinical trials, 12 (30.77%) were classified as in vitro studies, and only one (2.56%) involved experimental animal study. Of the agents evaluated for COVID-19 therapeutics, 15 (38.46%) were anti-viral, four (10.26%) antimalarial, four studies were immunotherapeutics (10.26%), two studies (5.13%) were antibacterial, while, one (2.56%) study wasfor antiparasitic , anticoagulant, anti-inflammatory, anti-viral/antimalarial, and anti-viral/herbal combination for each. Also, eight studies (20.51%) were antibiotic/antimalarial.. This review indicates that there is both a race and quest in the test of antiviral agents against COVID-19 and that arbidol seems to have dominated in the studies analyzed. The use of anticoagulants and antibiotics, such as teicoplanin and azithromycin/hydroxychloroquine were reported to also play a leading role in the management of the disease. Likewise, dexamethasone has been recently claimed to be effective in patients in need of respiratory assistance. Based on unresolved controversies and inconclusive findings, it could be said that generally, a single and specific therapeutics to COVID-19 is still a mirage. There is, thus, an urgent need to test more potent compounds and agents to establish much safer and highly efficacious drugs/agents for the disease, even as we continue to learn more about the disease as well as the characteristic of the virus.